Editas Medicine, Inc. EDIT

Rank #2093 · Nasdaq · $0.3B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

34.1

P/E

-1.1

P/B

0.75

ROE

-67.9%

Op. Margin

-777.2%

Debt Ratio

59%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -1.1x, P/B 0.75x. Ranks in the top 53% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -67.9%. Ranks in the top 93% of the universe.

Safety ★★★★☆

Good

Debt ratio 59%. Ranks in the top 26% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 63.9% year over year. Ranks in the top 6% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-1847
2017	–	$-0.0B	$-0.1B	$-0.0B	–	-618
2018	$0.0B	$-0.1B	$-0.1B	$-0.1B	-1605.6	-199
2019	$0.0B	$-0.1B	$-0.1B	$0.1B	-873.6	137
2020	$0.0B	$-0.1B	$-0.1B	$0.2B	-356.1	118
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	-686.4	76
2022	$0.1B	$-0.1B	$-0.1B	$0.3B	-148.6	47
2023	$0.0B	$-0.2B	$-0.2B	$0.4B	-756.1	39
2024	$0.0B	$-0.2B	$-0.2B	$0.6B	-1146.3	27
2025	$0.0B	$-0.3B	$-0.2B	$0.3B	-777.2	59